The products include eye shadow foundation blush face and body powders Some of these products are in the form of liquid and creams but 57 are powder products that pose an increased risk of inhalation hazards In 1976 the Cosmetic Toiletry and Fragrance Association CTFA developed specifications for cosmetic talc purity including detection of asbestos to differentiate from industrial uses However talc mined for both cosmetic use or industrial use comes from the same sources and carries the same risk of potential contamination.5 Yet the U.S.

The products include eye shadow foundation blush face and body powders Some of these products are in the form of liquid and creams but 57 are powder products that pose an increased risk of inhalation hazards In 1976 the Cosmetic Toiletry and Fragrance Association CTFA developed specifications for cosmetic talc purity including detection of asbestos to differentiate from industrial uses However talc mined for both cosmetic use or industrial use comes from the same sources and carries the same risk of potential contamination.5 Yet the U.S.

Target group of this questionnaire Questions are addressed to the whole supply chain including industry associations, importers, distributors and downstream users.

Target group of this questionnaire Questions are addressed to the whole supply chain including industry associations, distributors and downstream users.

Target group of this questionnaire Questions are addressed to the whole supply chain including industry associations, manufacturers, importers, distributors and downstream users.

Target group of this questionnaire Questions are addressed to the whole supply chain including industry associations, importers, distributors and downstream users.

Target group of this questionnaire Questions are addressed to the whole supply chain including industry associations, importers, distributors and downstream users.

Annex II - Honeywell submissions within the 2nd Call for Evidence (CfE) on PFAS restriction Honeywell Europe N.V.

Share of cosmetic products and product versions containing PFAS*. ............. 53 Table A.31.

Til: Jeppe Kramer Jrgensen (EM-DEP) ( @em.dk) Fra: Stellan Nrreskov Wulff (ffi@medicoindustrien.dk) Titel: SV: Mde ml.

. (\' i MedTech Europe from diagnosis to cure A Mrs Stella Kyriakides Commissioner for Health and Food Safety European Commission Rue de la Loi 200 B-1049 Brussels Brussels, 04-Dec-2023 Potential nomination of siloxanes D4, D5, and D6 to the Stockholm Convention on Persistent Organic Pollutants (POPs): securing patients' access to medical technologies Dear Commissioner, dear Mrs Kyriakides, On behalf of MedTech Europe, the European trade association representing the medical technology industry, I am contacting you today to raise your attention to the significant implications that a potential nomination of the siloxanes D4, D5 and D6 to the Stockholm Convention would entail for the medical technology sector, healthcare practitioners and patients who depend on continuous, uninterrupted supply of life-saving and life-sustaining medical technologies to satisfy their daily healthcare needs. (1) MedTech Europe is concerned with the significant risk posed by such a nomination on the vital use of D4, D5 and D6 in the manufacturing of silicone polymers, which are essential for the manufacture and use of many medical technology applications, including both medical devices and IVDs.1 (2) Additionally, the three siloxanes have been the subject of multiple regulatory measures in the European Union (EU) since 2017 by virtue of a REACH2 Restriction proposal3.

. (\' i MedTech Europe from diagnosis to cure A Mrs Stella Kyriakides Commissioner for Health and Food Safety European Commission Rue de la Loi 200 B-1049 Brussels Brussels, 04-Dec-2023 Potential nomination of siloxanes D4, D5, and D6 to the Stockholm Convention on Persistent Organic Pollutants (POPs): securing patients' access to medical technologies Dear Commissioner, dear Mrs Kyriakides, On behalf of MedTech Europe, the European trade association representing the medical technology industry, I am contacting you today to raise your attention to the significant implications that a potential nomination of the siloxanes D4, D5 and D6 to the Stockholm Convention would entail for the medical technology sector, healthcare practitioners and patients who depend on continuous, uninterrupted supply of life-saving and life-sustaining medical technologies to satisfy their daily healthcare needs. (1) MedTech Europe is concerned with the significant risk posed by such a nomination on the vital use of D4, D5 and D6 in the manufacturing of silicone polymers, which are essential for the manufacture and use of many medical technology applications, including both medical devices and IVDs.1 (2) Additionally, the three siloxanes have been the subject of multiple regulatory measures in the European Union (EU) since 2017 by virtue of a REACH2 Restriction proposal3.

The conditions proposed under RO2 are as follows: transitional period of 18 months for entry into force; a series of derogations limited in time (from 5 to 12 years); the only unlimited derogations concern active substances in biocidal products, plant protection products and human and veterinary medicinal products; anything that does not fall within the two previous cases and not expressly specified in the proposed derogations, will be banned at the end of the transitional period (e.g. food contact material for consumer use, non-stick pans, cosmetics, household products, etc.); As indicated by the authorities that prepared the restriction dossier, RO2 is considered the most proportionate and balanced scenario (p. 3 PFAS Restriction Report).

The conditions proposed under RO2 are as follows: transitional period of 18 months for entry into force; a series of derogations limited in time (from 5 to 12 years); the only unlimited derogations concern active substances in biocidal products, plant protection products and human and veterinary medicinal products; anything that does not fall within the two previous cases and not expressly specified in the proposed derogations, will be banned at the end of the transitional period (e.g. food contact material for consumer use, non-stick pans, cosmetics, household products, etc.); As indicated by the authorities that prepared the restriction dossier, RO2 is considered the most proportionate and balanced scenario (p. 3 PFAS Restriction Report).

CECHA EUROPEAN CHEMICALS AGENCY Annex to the ANNEX XV RESTRICTION REPORT PROPOSAL FOR A RESTRICTION SUBSTANCE NAME(S): Per- and polyfluoroalkyl substances (PFASs) IUPAC NAME(S): n.a.